Improved survival with ipilimumab in patients with metastatic melanoma FS Hodi, SJ O'day, DF McDermott, RW Weber, JA Sosman, JB Haanen, ... New England Journal of Medicine 363 (8), 711-723, 2010 | 17211 | 2010 |
Improved survival with vemurafenib in melanoma with BRAF V600E mutation PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ... New England Journal of Medicine 364 (26), 2507-2516, 2011 | 9129 | 2011 |
Pembrolizumab versus ipilimumab in advanced melanoma C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... New England Journal of Medicine 372 (26), 2521-2532, 2015 | 5891 | 2015 |
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ... The lancet oncology 16 (4), 375-384, 2015 | 2981 | 2015 |
Improved overall survival in melanoma with combined dabrafenib and trametinib C Robert, B Karaszewska, J Schachter, P Rutkowski, A Mackiewicz, ... New England Journal of Medicine 372 (1), 30-39, 2015 | 2921 | 2015 |
Adjuvant pembrolizumab versus placebo in resected stage III melanoma AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ... New England Journal of Medicine 378 (19), 1789-1801, 2018 | 1783 | 2018 |
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) J Schachter, A Ribas, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... The Lancet 390 (10105), 1853-1862, 2017 | 1292 | 2017 |
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study GA McArthur, PB Chapman, C Robert, J Larkin, JB Haanen, R Dummer, ... The lancet oncology 15 (3), 323-332, 2014 | 1207 | 2014 |
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study C Robert, A Ribas, J Schachter, A Arance, JJ Grob, L Mortier, A Daud, ... The Lancet Oncology 20 (9), 1239-1251, 2019 | 1036 | 2019 |
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma A Ribas, R Kefford, MA Marshall, CJA Punt, JB Haanen, M Marmol, ... Journal of clinical oncology 31 (5), 616, 2013 | 892 | 2013 |
Revised UK guidelines for the management of cutaneous melanoma 2010 JR Marsden, JA Newton‐Bishop, L Burrows, M Cook, PG Corrie, NH Cox, ... British Journal of Dermatology 163 (2), 238-256, 2010 | 625 | 2010 |
KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... N Engl J Med 372 (26), 2521-2532, 2015 | 596 | 2015 |
Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis SP D’Angelo, J Larkin, JA Sosman, C Lebbé, B Brady, B Neyns, ... Journal of Clinical Oncology 35 (2), 226, 2017 | 563 | 2017 |
The advantages of targeted protein degradation over inhibition: an RTK case study GM Burslem, BE Smith, AC Lai, S Jaime-Figueroa, DC McQuaid, ... Cell chemical biology 25 (1), 67-77. e3, 2018 | 537 | 2018 |
Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer M Reck, A Luft, A Szczesna, L Havel, SW Kim, W Akerley, MC Pietanza, ... Journal of Clinical Oncology 34 (31), 3740-3748, 2016 | 523 | 2016 |
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial A Le Cesne, JY Blay, I Judson, A Van Oosterom, J Verweij, J Radford, ... Journal of Clinical Oncology 23 (3), 576-584, 2005 | 522 | 2005 |
Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label … J Larkin, D Minor, S D'Angelo, B Neyns, M Smylie, WH Miller Jr, ... Journal of clinical oncology 36 (4), 383, 2018 | 520 | 2018 |
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial C Faivre-Finn, M Snee, L Ashcroft, W Appel, F Barlesi, A Bhatnagar, ... The Lancet Oncology 18 (8), 1116-1125, 2017 | 509 | 2017 |
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma MR Girotti, M Pedersen, B Sanchez-Laorden, A Viros, S Turajlic, ... Cancer discovery 3 (2), 158-167, 2013 | 413 | 2013 |
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma S Kelderman, B Heemskerk, H Van Tinteren, RRH Van Den Brom, ... Cancer Immunology, Immunotherapy 63, 449-458, 2014 | 365 | 2014 |